ABUS vs DVA · P/E 5.4, rev $6.2M vs P/E 14, rev $12.82B
Arbutus Biopharma Corp (ABUS) versus DaVita HealthCare Partners Inc (DVA) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported DVA revenue for 2024-12-31 was $12.82B. Net income was $1.25B. Revenue was up 5.6% from 2023-12-31 to 2024-12-31. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
Not investment advice. Open the ABUS and DVA stock pages for the full models.
Not investment advice.